Intermittent pacing therapy favorably modulates infarct remodeling

André Uitterdijk1 · Tirza Springeling1,2 · Kevin C. M. Hermans3 · Daphne Merkus1 · Vincent J. de Beer1 · Charlotte Gorsse-Bakker1 · Eric Mokelke4,5 · Evangelos P. Daskalopoulos3 · Piotr A. Wielopolski2 · Jack P. M. Cleutjens6 · W. Matthijs Blankesteijn3 · Frits W. Prinzen7 · Willem J. van der Giessen1 · Robert-Jan M. van Geuns1,2 · Dirk J. Duncker1

Received: 20 August 2014 / Accepted: 27 March 2017 / Published online: 6 April 2017 © The Author(s) 2017. This article is an open access publication

Abstract Despite early revascularization, remodeling and dysfunction of the left ventricle (LV) after acute myocardial infarction (AMI) remain important therapeutic targets. Intermittent pacing therapy (IPT) of the LV can limit infarct size, when applied during early reperfusion. However, the effects of IPT on post-AMI LV remodeling and infarct healing are unknown. We therefore investigated the effects of IPT on global LV remodeling and infarct geometry in swine with a 3-day old AMI. For this purpose, fifteen pigs underwent 2 h ligation of the left circumflex coronary artery followed by reperfusion. An epicardial pacing lead was implanted in the peri-infarct zone. After three days, global LV remodeling and infarct geometry were assessed using magnetic resonance imaging (MRI). Animals were stratified into MI control and IPT groups. Thirty-five days post-AMI, follow-up MRI was obtained and myofibroblast content, markers of extracellular matrix (ECM) turnover and Wnt/frizzled signaling in infarct and non-infarct control tissue were studied. Results showed that IPT had no significant effect on global LV remodeling, function or infarct mass, but modulated infarct healing. In MI control pigs, infarct mass reduction was principally due to a 26.2 ± 4.4% reduction in infarct thickness (P < 0.05), whereas in IPT pigs it was mainly due to a 35.7 ± 4.5% decrease in the number of infarct segments (P < 0.05), with no significant change in infarct thickness. Myofibroblast content of the infarct zone was higher in IPT (10.9 ± 2.1%) compared to MI control (5.4 ± 1.6%; P < 0.05). Higher myofibroblast presence did not coincide with alterations in expression of genes involved in ECM turnover or Wnt/frizzled signaling at 5 weeks follow-up. Taken together, IPT limited infarct expansion and altered infarct composition, showing that IPT influences remodeling of the infarct zone, likely by increasing regional myofibroblast content.

Keywords Myocardial infarction · Myofibroblasts · Infarct geometry · Infarct expansion · Infarct healing · Swine

Introduction

The prevalence of heart failure continues to rise worldwide [6, 31]. An important risk factor for heart failure is left-ventricular (LV) remodeling following acute myocardial
infarction (AMI), with infarct size as its principal deter-
iminant [6, 14, 28]. Despite advances in the treatment of
AMI and subsequent cardiac remodeling, a need exists for
novel adjunctive therapies [5]. Current strategies under
investigation for cardioprotection include pharmacologi-
cal agents or application of brief mechanical interruptions of
coronary blood flow either before ischemia or during early
reperfusion to protect the myocardium by reducing infarct
size [9, 12]. In addition, evidence from experimental
studies shows that intermittent pacing therapy (IPT) is
capable of limiting infarct size not only when applied prior
to ischemia [21, 46] but also when applied during early
reperfusion [1, 3, 45], resulting in a trend towards blunting
of subsequent LV remodeling [2]. Importantly, a recent
clinical study confirmed pacing therapy to be effective at
reducing infarct size in patients, when started at reperfusion
[47].

Presently, it remains incompletely understood whether
IPT is capable of limiting LV remodeling independent of
its protection against acute myocardial necrosis, i.e.,
when started a few days after reperfusion. Consequently,
the aim of the present study was to investigate the
effects of dysynchronous IPT of the left ventricle
(IPTVVI), when started in the sub-acute phase after
reperfusion. Consequently, animals received IPTVVI (3
9
min
b.i.d.) throughout the five weeks post-AMI.

Materials and methods

Experiments were performed in thirty-six 5–6-month-old
Yorkshire x Landrace pigs of either sex and were con-
ducted in compliance with the “Guide for the Care and use
of Laboratory Animals” and after written approval of the
Animal Care Committee of the Erasmus MC.

Acute effects of IPTAAI and IPTVVI on LV
function

In four chronically instrumented swine we assessed safety and
proper functioning of the pacemakers by investigating the
acute hemodynamic responses to intermittent dysynchronous
pacing of the left ventricle (IPTVVI) in comparison with
intermittent synchronous atrial pacing (IPTAAI). See Sup-
complemental Methods and Results for detailed protocol and

Effects of chronic IPTVVI on global LV
and regional infarct remodeling

Surgery

Swine (n = 27) were sedated [ketamine 20 mg/kg intra-
muscular (IM); midazolam, 1 mg/kg, IM; atropine 1 mg,
IM], anesthetized [thiopental sodium, 15 mg/kg, intra-
venous (IV)] and intubated. Anesthesia was maintained
with fentanyl (20 μg/kg/h, IV) until LCx occlusion, fol-
lowed by isoflurane (1–2% v/v). Antibiotic prophylaxis
consisted of procaine benzylpenicillin (20 mg/kg, IM) and
dihydrostreptomycin (25 mg/kg, IM). Following thoraco-
tomy via the third left intercostal space, a polyvinylchlor-
ride catheter was placed in the aortic arch, the pericardium
was opened and the proximal LCx was dissected. A
unipolar epicardial lead was actively fixed in the anticipa-
pated anterior infarct border zone, followed by 2 h of LCx
occlusion. The pericardium and chest were closed and the
animals were allowed to recover, receiving analgesia
(buprenorphine, 0.01 mg/kg/day, IM) for 48 h. Pacemakers
were interrogated weekly. Six swine died during the AMI
procedure; two swine died during the first 24 h post-AMI;
one swine died during transportation to the MRI at 3 days.

Experimental protocol

Three days after AMI, cardiac MRI was performed. Swine
were sedated and intubated as described above. Mechanical
ventilation and peri-imaging breath holds were performed
using a mobile ventilator. During MRI, anesthesia was
maintained with fentanyl (20 μg/kg/h, IV) and thiopental
sodium (100 mg bolus). Muscle relaxation was achieved
using pancuronium bromide (2–4 mg, IV). Post-imaging,
animals received antibiotic prophylaxis as described above
and were allowed to recover. Then, animals were ran-
donized to either MI control or IPTVVI and pacemakers
remained switched off (MI control) or were started
(IPTVVI). Importantly, none of the remaining 18 swine
died prematurely after stratification into MI control
(n = 11) or IPTVVI (n = 7) groups. The IPTVVI pacing
protocol was applied every 12 h (6 am and 6 pm), con-
sisting of three times 5-min of pacing at 30 beats/min
above sinus rhythm (AV-delay 10 ms) separated by 5-min
of normal sinus rhythm. Post hoc analysis of pacemaker
readouts could not confirm proper pacing in one IPTVVI
animal, whereas in the MI control group two animals
received unplanned indiscriminate pacing. Consequently,
for final analysis six swine were included in the IPTVVI
group and nine swine were included in the MI control
group. At one and five weeks post-AMI arterial blood
samples were collected in subsets of animals (n = 5 per
group). Five weeks after onset of treatment, cardiac MRI
measurements were repeated and animals were killed for histological and molecular analysis of the infarct zone.

**Cardiac magnetic resonance imaging**

Cardiac MRI was performed and analyzed on a 3T scanner as described before [4, 38]. Global and regional cardiac function and infarct geometry were assessed at baseline (3 days post-AMI), i.e., before treatment and at 5 weeks follow-up (see Supplemental Methods and Results).

**Biomarkers**

Arterial blood samples were collected 1 and 5 weeks post-AMI in EDTA tubes (n = 5) and plasma was stored at −80 °C. Markers of inflammation (TNFα) and extracellular matrix turnover (MMP-9, TIMP-1) were quantified using dedicated porcine enzyme-linked immunosorbent assays (ELISA) according to manufacturer’s instructions (see Supplemental Methods and Results).

**Histology**

At 5 weeks follow-up, transverse sections of infarct tissue were fixed in 4% formaldehyde and embedded in paraffin. To quantify myofibroblasts in the infarct area, sections were stained for alpha smooth muscle actin (αSMA; [44]; see Supplemental Methods and Results). Data were expressed as myofibroblast area/total tissue area (%). In addition, lateral wall myocardial tissue of five additional weight-matched healthy swine was quantified for myofibroblast content.

To quantify total collagen content and discriminate collagen fiber type in the infarct area, sections were stained with 0.1% picrosirius red in saturated picric acid (n = 6 per group). Collagen content in the infarct region was expressed as stained area/total infarct area (%) using bright field images (four photos per animal). Collagen fiber types were assessed by circular polarizing microscopy in which five polarizing colors were discerned: red (type I collagen, mature), orange, yellow, green, and teal (type III collagen, immature) to discriminate between mature and immature collagen and were expressed as polarized area of interest/total polarized area (%).

**RT-PCR**

Infarct tissue from all animals as well as normal myocardium of the weight-matched non-MI control group (n = 5) was homogenized and RNA was isolated. The isolated RNA was assessed for concentration and purity (A260/A280 ratio), and reverse-transcribed into cDNA (see Supplemental Methods and Results). The expression of 21 genes related to myofibroblast presence, regulation or differentiation, were quantified as well as seven genes involved in extracellular matrix turnover (see Table 2 and Supplemental Methods and Results). Quantification of gene expression was performed using the comparative Ct (ΔCt) method and results are expressed as ratios to the housekeeping gene cyclophilin.

**Statistical analysis**

All data are expressed as mean ± SEM. Data were analyzed using two-way (time × treatment) RM-ANOVA followed by post hoc testing, when appropriate, or within treatment group differences with paired t testing, and between treatment group differences with unpaired t testing (SPSS 15.0, IBM, Armonk, NY, USA). One-way ANOVA testing with Fisher’s least significant difference correction (LSD) was used to analyze gene expression data. P ≤ 0.05 (two-tailed) was considered statistically significant.

**Results**

**Acute effects of IPTAAI and IPTVVI on LV function**

Safety and proper functioning of ventricular pacing protocols were ascertained in four pigs as evidenced by the absence of ventricular arrhythmias and a programmed increase in heart rate of 30 beats/min (see Supplemental Methods and Results and Supplemental Figure 1 for details).

**Effects of chronic IPTVVI on global LV and regional infarct remodeling**

Table 1 summarizes global LV anatomy, function and infarct geometry data at baseline and at follow-up. In MI control animals, two hours of occlusion of the LCx resulted in AMI that comprised 31 ± 2% of the LV. Already at 3-day post-AMI, LV end-diastolic volume (EDV, 80 ± 3 ml) and end-systolic volume (ESV, 54 ± 2 ml) were larger as compared to EDV (68 ± 3 ml) and ESV (30 ± 2 ml) in a historical control group of healthy adolescent swine of similar age [30]. MI resulted in a depressed ejection fraction (EF) of 33 ± 2%, compared to 55 ± 3% in normal healthy swine [30]. During the 5 weeks follow-up, total LV mass did not change, as the increase in mass of the remote myocardium was balanced by an equivalent decrease in infarct mass (Table 1). EDV and ESV further increased to 113 ± 5 and 68 ± 3 ml, respectively, with EF tending to slightly recover from 33 ± 2 to 40 ± 2% (P = 0.06). The increase in EDV over
time in swine with MI was in part attributable to physiological growth of the heart, as EDV in healthy swine showed a modest increase from 68 ± 3 to 91 ± 6 ml [30]. In contrast to the increase in ESV over time in swine with MI (from 54 ± 3 to 68 ± 3 ml), there was a negligible increase in ESV in healthy swine (from 30 ± 2 to 32 ± 3 ml), associated with an increase in EF from 55 ± 3 to 64 ± 3% [30]. These findings indicate that MI resulted in LV remodeling and dysfunction that was already observed early at 3 days and was sustained throughout the 5 weeks follow-up period.

Global LV and infarct geometry parameters showed no significant differences between IPTVVI and MI control (Table 1) at the 3-day post-AMI baseline. Moreover, the changes in global LV anatomy and function during 5 weeks of follow-up were not different between IPTVVI and MI control. However, infarct geometry responded markedly to IPTVVI (Table 1; Fig. 1). In MI control animals, infarct mass decreased over time as a result of a significant decrease in infarct thickness with no significant changes in infarct length or circumference, and no changes

| Table 1 | Global LV function and infarct geometry |
|---------|-----------------------------------------|
|         | Post-MI                                  |
|         | 3 days BL | 37 days FU |         |          |
| Global LV anatomy and function |
| Body weight (kg) |
| MI control | 29 ± 0 | 38 ± 1* |
| IPT | 28 ± 1 | 37 ± 1* |
| LV mass (g) |
| MI control | 56 ± 1 | 58 ± 1 |
| IPT | 55 ± 2 | 55 ± 1 |
| Heart rate (bpm) |
| MI control | 93 ± 3 | 80 ± 6 |
| IPT | 100 ± 6 | 78 ± 11 |
| End-diastolic volume (ml) |
| MI control | 80 ± 3 | 113 ± 5* |
| IPT | 81 ± 2 | 110 ± 8* |
| End-systolic volume (ml) |
| MI control | 54 ± 3 | 68 ± 3* |
| IPT | 53 ± 2 | 67 ± 8 |
| Stroke volume (ml) |
| MI control | 27 ± 2 | 45 ± 4* |
| IPT | 28 ± 2 | 43 ± 3* |
| Ejection fraction (%) |
| MI control | 33 ± 2 | 40 ± 2** |
| IPT | 35 ± 3 | 40 ± 3* |
| Infarct geometry |
| Remote LV mass (g) |
| MI control | 39 ± 1 | 47 ± 1* |
| IPT | 38 ± 1 | 46 ± 1* |
| Infarct mass (g) |
| MI control | 17.6 ± 1.4 | 11.7 ± 0.8* |
| IPT | 17.1 ± 1.2 | 9.3 ± 0.9* |
| Infarct size (% LV) |
| MI control | 31 ± 2 | 20 ± 1* |
| IPT | 31 ± 2 | 17 ± 2* |
| Infarct thickness (mm) |
| MI control | 6.2 ± 0.2 | 4.5 ± 0.2* |
| IPT | 5.9 ± 0.2 | 4.9 ± 0.3 |
| Infarct length (#slices) |
| MI control | 7.8 ± 0.6 | 8.3 ± 0.6 |
| IPT | 8.8 ± 0.3 | 8.0 ± 0.5* |
| Infarct length (mm) |
| MI control | 47 ± 4 | 50 ± 4 |
| IPT | 53 ± 2 | 48 ± 3* |
| Infarct circumference (#segments) |
| MI control | 13.5 ± 0.8 | 12.0 ± 1.1 |
| IPT | 13.6 ± 1.6 | 9.4 ± 1.3* |
| Infarct circumference (mm) |
| MI control | 62 ± 3 | 65 ± 6 |
| IPT | 61 ± 5 | 52 ± 5 |

Fig. 1 Effect of IPTVVI on infarct geometry. Percent changes in infarct geometry from 3 days baseline values at 5-week follow-up in eight MI control (white bars) and six IPTVVI (gray bars) swine. Shown are changes in infarct mass, infarct thickness, total number of infarcted segments, number of infarcted slices, and average circumferential infarct length. Data are mean ± SEM; *P ≤ 0.05 vs. corresponding BL; **P ≤ 0.10, change by IPT vs. change in control.
in the total number of infarcted segments. In contrast, in IPTVVI animals, the reduction in infarct mass was primarily due to a decrease in total number of infarcted segments (comprising reductions in both infarct length and circumference), with no significant decrease in infarct thickness. The latter could have played a role in preventing the reduction in infarct mass from reaching statistical significance compared to MI control group ($P = 0.07$; Fig. 1).

Infarct composition

Histological quantification of αSMA positive cells in the infarct region showed a significantly higher amount of myofibroblasts in the infarct area in IPTVVI (10.9 ± 2.1%) than in MI control (5.4 ± 1.6%) swine (Fig. 2). αSMA quantification of referent control tissue (excluding the coronary microvasculature) equaled zero and confirmed the absence of myofibroblasts in healthy myocardial tissue. mRNA-expression data for αSMA between IPTVVI and MI control confirmed the IPTVVI-induced increase in αSMA in histological findings ($P = 0.04$, see Table 2).

Canonical Wnt/frizzled signaling is activated upon injury including myocardial infarction [13, 50]. Indeed, the increased myofibroblast presence in infarcted tissue as compared to non-MI tissue was accompanied by activation of the Wnt/frizzled signaling, as evidenced by increased presence of the Fzd2 receptor and its co-receptor LRP5. However, downstream targets of canonical Wnt/frizzled signaling (axis inhibition protein 2 (Axin), adenomatous polyposis coli (APC) and β-catenin) were not altered in infarcted tissue as compared to non-MI tissue. The inflammatory markers transforming growth factor β (TGFβ) were also not altered in MI as compared to non-MI tissue, and its receptors TGFβ1R and TGFβ2R were decreased. Overall, TGFβ-signaling appeared to be reduced in MI as compared to non-MI tissue, as evidenced by a decrease in PAI1. However, IPTVVI had no effect on either Wnt/frizzled or TGFβ-signaling (Table 2), while circulating levels of TNFα were also not different between IPT and MI control animals (Fig. 3).

Consistent with the role of myofibroblasts in extracellular matrix (ECM) production and turnover, Col1a1 expression at follow-up was significantly increased in IPTVVI animals compared to MI control ($P = 0.04$), while Col3a1 expression was elevated in both MI control and IPT animals (Table 2).

Histological quantification of total collagen content showed no differences between MI control and IPTVVI infarct collagen content at 5 weeks follow-up (73 ± 3 vs. 78 ± 4%, respectively, $P = 0.34$). Furthermore, collagen composition, expressed as the percentage type I collagen fiber (red, mature; 52 ± 7 vs. 65 ± 6%, $P = 0.22$) and type III collagen (teal, immature; 10 ± 2 vs. 7 ± 1%, respectively, $P = 0.12$) were not different between groups (See Supplemental Methods and Results for individual data).

Circulating plasma levels of extracellular matrix turnover (MMP-9 and TIMP-1), measured at 1 and 5 weeks post-AMI, did not differ significantly between treatment groups (Fig. 3), although there was a trend towards an increase in TIMP-1 expression in the infarcted area in IPTVVI vs. MI control ($P = 0.09$, two-tailed), that together with the increased Col1a1 expression may reflect increased ECM turnover.

Discussion

The present study is the first to investigate the effects of dysynchronous intermittent ventricular pacing (IPTVVI), initiated three days after acute myocardial infarction (AMI) and continued for 5 weeks, on global and regional LV remodeling and infarct geometry in a clinically relevant large animal model. The major findings were that (1) IPTVVI had no effect on global LV remodeling or function, but (2) had a marked effect on infarct remodeling by decreasing the number of infarcted segments without

---

**Fig. 2** IPTVVI increases myofibroblast presence in the infarct region. Left panel αSMA stained infarct tissue of two MI control and two IPTVVI swine (magnification ×20). Brown staining indicates myofibroblasts. Right panel percent αSMA-positive cells in infarct tissue from eight MI control (white bar) and six IPTVVI (gray bar) swine. Data are mean ± SEM; *$P \leq 0.05$ vs. MI control.
Table 2 Expression of genes related to myofibroblasts and extracellular matrix biology

|                                | Non-MI control | MI control | IPT          |
|--------------------------------|----------------|------------|--------------|
| **Myofibroblast presence, regulation and differentiation** |                |            |              |
| αSMA                           | 0.5 ± 0.1      | 0.7 ± 0.1  | 1.2 ± 0.3*   |
| Vimentin                       | 2.7 ± 0.6      | 1.7 ± 0.5  | 1.6 ± 0.4    |
| Desmin                         | 0.4 ± 0.1      | 0.4 ± 0.1  | 0.3 ± 0.1    |
| SPARC                          | 0.5 ± 0.1      | 1.6 ± 0.5  | 1.9 ± 0.7**  |
| Tenascin-C                     | 0.1 ± 0.1      | 1.5 ± 0.9  | 0.6 ± 0.2*   |
| VEGF-A                         | 1.3 ± 0.4      | 0.6 ± 0.1**| 0.6 ± 0.3**  |
| β-Catenin                      | 0.7 ± 0.3      | 0.6 ± 0.1  | 0.4 ± 0.1    |
| TGFβ1                          | 0.8 ± 0.3      | 0.8 ± 0.1  | 0.5 ± 0.1    |
| TGFβ2                          | 2.7 ± 1.0      | 1.8 ± 0.6  | 1.4 ± 0.1    |
| TGFβ3                          | 0.2 ± 0.1      | 6.1 ± 2.2**| 5.2 ± 1.8    |
| TGFβ1R                         | 3.3 ± 1.3      | 1.1 ± 0.2* | 0.9 ± 0.1*   |
| TGFβ2R                         | 1.7 ± 0.5      | 0.8 ± 0.1* | 0.7 ± 0.1*   |
| Fzd2                           | 0.4 ± 0.1      | 1.5 ± 0.4**| 1.7 ± 0.3*   |
| Fzd4                           | 0.9 ± 0.2      | 1.3 ± 0.3  | 0.9 ± 0.2    |
| LRP5                           | 0.2 ± 0.1      | 0.8 ± 0.2* | 0.5 ± 0.2    |
| LRP6                           | 1.1 ± 0.3      | 0.7 ± 0.1  | 0.7 ± 0.1    |
| LOX                            | 2.1 ± 0.6      | 2.0 ± 0.7  | 3.6 ± 0.7    |
| APC                            | 0.8 ± 0.2      | 0.8 ± 0.2  | 0.8 ± 0.1    |
| Axin2                          | 3.1 ± 1.2      | 3.6 ± 1.2  | 3.5 ± 1.0    |
| ID1                            | 0.2 ± 0.1      | 0.6 ± 0.2  | 0.7 ± 0.2    |
| PAI1                           | 2.6 ± 1.2      | 1.0 ± 0.2**| 0.6 ± 0.2*   |
| **Extracellular matrix composition and turnover** |                |            |              |
| Col1a1                         | 0.9 ± 0.2      | 2.1 ± 0.7  | 4.7 ± 1.3*   |
| Col1a2                         | 2.7 ± 0.7      | 1.9 ± 0.6  | 3.5 ± 1.3    |
| Col3a1                         | 0.3 ± 0.1      | 1.7 ± 0.5**| 2.0 ± 0.6*   |
| MMP-2                          | 1.4 ± 0.4      | 1.7 ± 0.5  | 2.5 ± 0.7    |
| MMP-9                          | 1.9 ± 0.6      | 4.5 ± 1.6  | 4.5 ± 1.5    |
| TIMP-1                         | 0.1 ± 0.1      | 1.5 ± 0.4  | 3.4 ± 1.5*   |
| CTGF                           | 1.6 ± 1.3      | 1.8 ± 0.5  | 0.9 ± 0.3    |

Data are presented as mean ± SEM and expressed as ratios to housekeeping gene cyclophilin; MI control: n = 9; IPT: n = 6, non-MI control: n = 5

APC: adenomatous polyposis coli, Axin: axis inhibition protein, αSMA: alpha smooth muscle actin, Col: collagen, CTGF: connective tissue growth factor, Fzd: frizzled, ID: inhibitor of DNA binding, LOX: lysyl oxidase, LRP: low-density lipoprotein receptor-related protein, MMP: matrix metalloproteinase, PAI: plasminogen activator inhibitor, RT-qPCR: reverse transcriptase quantitative polymerase chain reaction, SPARC: secreted protein acidic and rich in cysteine, TGF: transforming growth factor, TIMP: tissue inhibitor of metalloproteinases, VEGF: vascular endothelial growth factor A

*a P ≤ 0.05 vs. non-MI control
**a P ≤ 0.10 vs. non-MI control
†† P ≤ 0.05 IPT vs. corresponding MI control
††† P ≤ 0.10 IPT vs. corresponding MI control

changing infarct thickness. (3) Additionally, IPTVVI increased myofibroblast content in the infarcted area, (4) without changing circulating markers of inflammation and extracellular matrix turnover. These findings provide evidence that intermittent electrical stimulation of the left ventricle may represent a novel means to modulate scar remodeling after MI.

IPT in AMI and post-AMI remodeling

Several studies in swine [21] and rabbits [45, 46] have shown that pretreatment with ventricular, but not atrial [27], pacing is capable of limiting myocardial infarct size. Subsequent studies have demonstrated that not only preconditioning [21, 45, 46], but also postconditioning with brief periods of ventricular pacing in the early reperfusion phase [1–3, 45] can limit myocardial infarct size. Moreover, the effects of this early protection against myocardial necrosis were sustained over a six week period, resulting in a trend towards blunted LV remodeling and improved LV function [2]. The present study is the first to investigate the effects of prolonged IPT on infarct remodeling, independent of its protection against acute myocardial necrosis in a preclinical animal model. The results of this study clearly demonstrate that IPTVVI started 3 days after reperfusion, at a time when necrosis can no longer be affected, significantly influenced remodeling of the infarct region.

Early studies in humans in the pre-thrombolysis era, reported disproportionate thinning and stretching of the infarcted segment [18, 48, 49]. Recent post-thrombolysis studies in humans with reperfused AMI confirm that regional myocardial wall thinning represents (transmural) myocardial infarction [35]. Furthermore, limited scar burden is associated with improved contractility [35] and blunted remodeling [28], whereas rupture-prone cardiac aneurysms are the consequence of continued ventricular wall thinning [22]. Also, late dilatation of the LV after primary percutaneous intervention remains of clinical significance [37] and may represent a potential target of IPTVVI. Thus, the IPTVVI-induced alteration of infarct geometry may mitigate the sequence of events leading to ventricular wall thinning and limit LV remodeling. Although significant changes in infarct geometry and composition were observed in the present study, these alterations did not yet translate into favorable global LV remodeling at 5 weeks follow-up. This finding, which is similar to previous observations with cell-therapy studies in swine [29], as well as humans [19], with AMI, suggests that more pronounced changes in infarct geometry are required to translate into benefits at the global LV level.
This may also explain why a recent clinical study on peri-infarct zone pacing after AMI (PRomPT Trial) reported no difference in LV function or geometry at 18-month follow-up [39]. A limitation of the present study is that we investigated only a single algorithm of pacing therapy, so that we cannot exclude that other algorithms or pacing protocols may produce larger regional effects that do translate into global LV improvements [3]. Clearly, future studies, are necessary to optimize the onset, timing, duration and mode of pacing therapy.

IPT and infarct geometry: role of myofibroblasts

The infarct zone is increasingly being appreciated as an area with relevant biological activity and therapeutic potential [8, 40]. Cardiac fibroblasts, including the active collagen-secreting myofibroblasts, are the dominant cell type in the infarct region and are recognized as essential in infarct remodeling [7, 20, 41, 43]. Myofibroblasts typically appear in the infarct area at 4–5 days after AMI, reach a peak at 1–2 weeks and continue to reside up to at least 4 weeks [10] and possibly months to years [43]. In the present study, IPTVVI, started at three days post-AMI, increased myofibroblast numbers in the infarct zone significantly. Myofibroblasts could have contributed to the geometric changes in the infarct region produced by IPTVVI in several ways. First, in the infarcted myocardium, myofibroblasts are responsible for collagen turnover thus contributing to the delicate balance between ECM synthesis and degradation [43]. Consistent with a role of myofibroblasts in ECM synthesis, Col1a1 expression was increased by IPTVVI. Moreover, a trend towards increased expression of TIMP-1 was found in infarcts of IPTVVI animals (P = 0.09) compared to MI control, which is consistent with the observations of Mukherjee et al. [32] that TIMP-1 co-localizes with myofibroblasts within the infarct zone. Although the increased Col1a1 expression and the trend towards an increase in TIMP-1 did not translate into an increase in collagen as measured with histology, it is plausible that myofibroblasts, a rich source of bioactive molecules [34], modulated infarct geometry by affecting ECM turnover. Second, myofibroblasts are capable of tonic contraction, and could therefore improve structural integrity of the scar and increase mechanical strength in the (sub)acute phase [43]. Particularly, the latter is in concordance with the geometrical changes observed in the present study.

The exact mechanism by which IPTVVI influenced myofibroblast presence was not determined in the present study. However, it is well known that LV pacing results in considerable changes in LV contraction patterns, even in the peri-infarct zone [25, 45], resulting in alterations in regional stretch and loading conditions [17, 33, 36, 46]. Since mechanical tension is an important stimulus for cardiac fibroblast to myofibroblast differentiation [11, 15, 16, 26], it is likely that regional alterations in myocardial stretch produced by IPTVVI stimulated resident fibroblasts to differentiate into myofibroblasts.

No change in circulating arterial plasma levels of the inflammatory marker TNFα was found in IPTVVI vs. MI control swine, at either 1 or 5 weeks after AMI, indicating that the effect of pacing on release of these proteins in pigs with infarcts was not discernible in the systemic circulation even as early as 1 week post-AMI. Hence, altered myofibroblast presence within the infarcted area of IPTVVI treated swine was likely the result of local effects on myofibroblast recruitment and/or differentiation. As myofibroblast migration and differentiation are initiated in the early phase after MI, expression studies at 5-week follow-up can by definition not identify which molecular mechanisms underlie the higher myofibroblast presence. Interestingly, the expression of the Fzd2 receptor, involved in myofibroblast homeostasis [24], was increased in both MI control and IPTVVI treated animals, which may have served to maintain the myofibroblasts in the infarcted region. It has previously been shown that activation of the

Fig. 3 Circulating levels of markers of extracellular matrix and inflammation. Markers for extracellular matrix and inflammation in arterial plasma of five control (white bars) and five IPTVVI (gray bars) swine. Data are mean ± SEM; *P ≤ 0.05 vs. MI control

![Fig. 3](image-url)
TGFβ signaling pathway increases myofibroblast presence [23], and therefore it is possible that this pathway was only activated in the early phase of IPTVVI. This is also suggested by a study in swine, in which continuous low dose electrical stimulation within the infarct region, not only resulted in higher numbers of myofibroblasts, but also in elevated TGFβ-R1 activity, when measured as early as one week after onset of stimulation [32]. Expression of TGFβ-R1 and PAI-1, a measure for TGFβ-R1 signaling were downregulated in both the MI control and IPTVVI group as compared to healthy control animals underlining the transient nature of the local inflammatory responses at the molecular level to regional electrical stimulation. Although in agreement with a previous study from our laboratory [42], TGFβ3 was upregulated in the infarcted tissue, this was not altered by IPTVVI, making it unlikely that activation of the TGFβ-pathway at five weeks follow-up contributed to the increased presence of the myofibroblasts in the IPTVVI treated animals.

In conclusion, the present study shows that 5 weeks of IPTVVI, a regionally targeted non-pharmaceutical approach that was safe (no arrhythmias and maintained cardiac output), favorably influenced the infarct remodeling process, likely by increasing myofibroblast content in the infarct region. Thus, whereas MI control swine showed a reduction in infarct mass over the 5-week follow-up period, which was principally due to infarct thinning, IPTVVI resulted in a reduction in infarct mass that was principally due to a decrease in the number of infarcted LV segments while infarct thinning was prevented. Histological assessment revealed increased numbers of myofibroblasts in the infarct zone. Taken together, these findings suggest that IPT in the peri-infarct zone represents a novel adjunctive therapy to favorably modulate infarct healing in patients with acute myocardial infarction.

Compliance with ethical standards

Conflict of interest This study was financially supported by Boston Scientific/Guidant. Eric Mokelke is a former Boston Scientific Employee.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Abwainy A, Babiker F, Akhtar S, Benter IF (2016) Endogenous angiotensin-(1–7)/Mas receptor/NO pathway mediates the cardioprotective effects of pacing postconditioning. Am J Physiol Heart Circ Physiol 310:H104–H112. doi:10.1152/ajpheart.00121.2015

2. Babiker FA, Lorenzen-Schmidt I, Mokelke E, Vanagt WY, Delhaas T, Waltenberger J, Cleutjens JP, Prinzen FW (2010) Long-term protection and mechanism of pacing-induced postconditioning in the heart. Basic Res Cardiol 105:523–533. doi:10.1007/s00395-010-0095-2

3. Babiker FA, van Golde J, Vanagt WY, Prinzen FW (2012) Pacing postconditioning: impact of pacing algorithm, gender, and diabetes on its myocardial protective effects. J Cardiovasc Transl Res 5:727–734. doi:10.1007/s12265-012-9390-7

4. Baks T, van Geuns RJ, Biagini E, Wielopolski P, Mollet NR, Cademartiri F, Boersma E, van der Giessen WJ, Krestin GP, Duncker DJ, Serruys PW, de Feyter PJ (2005) Recovery of left ventricular function after primary angioplasty for acute myocardial infarction. Eur Heart J 26:1070–1077. doi:10.1093/eurheartj/ehi131

5. Bell RM, Botker HE, Carr RD, Davidson SM, Downey JM, Dutka DP, Heusch G, Ibanez B, Macalister R, Stoppe C, Ovize M, Redington A, Walker JM, Yellon DM (2016) 9th Hatter Biannual Meeting: position document on ischaemia/reperfusion injury, conditioning and the ten commandments of cardioprotection. Basic Res Cardiol 111:41. doi:10.1007/s00395-016-0558-1

6. Braunwald E (2013) Heart failure. JACC Heart Fail 1:1–20. doi:10.1016/j.jchf.2012.10.002

7. Brown RD, Ambler SK, Mitchell MD, Long CS (2005) The cardiac fibroblast: therapeutic target in myocardial remodeling and failure. Annu Rev Pharmacol Toxicol 45:657–687. doi:10.1146/annurev.pharmtox.45.120403.095802

8. Cleutjens JP, Blanksteijn WM, Daemen MJ, Smits JF (1999) The infarcted myocardium: simply dead tissue, or a lively target for therapeutic interventions. Cardiovasc Res 44:232–241. doi:10.1016/j.cardiores.2007.01.014

9. Dirksen MT, Laarman GJ, Simoons ML, Duncker DJ (2007) Reperfusion injury in humans: a review of clinical trials on reperfusion injury inhibitory strategies. Cardiovasc Res 74:343–355. doi:10.1016/j.cardiores.2007.01.014

10. Frangogiannis NG, Michael LH, Entman ML (2000) Myofibroblasts in reperfused myocardial infarcts express the embryonic form of smooth muscle myosin heavy chain (SMyemb). Cardiovasc Res 48:89–100. doi:10.1016/S0008-6363(00)00158-9

11. Fujii K, Nagai R (2013) Contributions of cardiomyocyte–cardiac fibroblast–immune cell interactions in heart failure development. Basic Res Cardiol 108:357. doi:10.1007/s00395-013-0357-x

12. Hausenloy DJ, Yellon DM (2013) Myocardial ischemia–reperfusion injury: a neglected therapeutic target. J Clin Invest 123:92–100. doi:10.1172/JCI62874

13. Hermans KC, Daskalopoulos EP, Blanksteijn WM (2012) Interventions in Wnt signaling as a novel therapeutic approach to improve myocardial infarct healing. Fibrogenesis Tissue Repair 5:16. doi:10.1186/1755-1536-5-16

14. Heusch G, Libby P, Gersh B, Yellon D, Bohm M, Lopaschuk G, Opie L (2014) Cardiovascular remodelling in coronary artery disease and heart failure. Lancet 383:1933–1943. doi:10.1016/S0140-6736(14)60107-0

15. Hinz B, Gabbiani G (2003) Mechanisms of force generation and transmission by myofibroblasts. Curr Opin Biotechnol 14:538–546. doi:10.1016/j.copbio.2003.08.006

16. Hinz B, Mastrangelo D, Iselin CE, Chapronnier C, Gabbiani G (2001) Mechanical tension controls granulation tissue contractile activity and myofibroblast differentiation. Am J Pathol 159:1009–1020. doi:10.1016/S0002-9440(10)61776-2

17. Huang CH, Wang JS, Chiang SC, Wang YY, Lai ST, Weng ZC (2004) Brief pressure overload of the left ventricle preconditions rabbit myocardium against infarction. Ann Thorac Surg 78:628–633. doi:10.1016/j.jathoracsur.2004.01.046
18. Hutchins GM, Bulkley BH (1978) Infarct expansion versus extension: two different complications of acute myocardial infarction. Am J Cardiol 41:1127–1132. doi:10.1016/0002-9149(78)90869-X
19. Janssens S, Dubois C, Bogaert J, Theunissen K, Deroose C, Desmet W, Kalantzis M, Herbots L, Sinnaeve P, Den J, Maertens J, Rademakers F, Dymarkowski S, Gheyens O, Van Cleemput J, Bormans G, Nuys J, Belmans A, Mortelmans L, Boogaerts M, Van de Werf F (2006) Autologous bone marrow-derived stem cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial. Lancet 367:113–121. doi:10.1016/s0140-6736(05)67861-0
20. Jivraj N, Phinikaridou A, Shah AM, Botnar RM (2014) Molecular imaging of myocardial infarction. Basic Res Cardiol 109:397. doi:10.1007/s00395-013-0397-2
21. Koning MM, Gho BC, van Klaarwater E, Opstal RL, Duncker DJ, Verdonk PD (1996) Rapid ventricular pacing produces myocardial protection by nonischemic activation of KATP+ channels. Circulation 93:178–186. doi:10.1161/01.CIR.93.1.178
22. Kumar Goud P, Bakkannavar SM, Chinmayee P (2013) Cardiac aneurysm: a nature’s way of correction. Am J Forensic Med Pathol 34:228–230. doi:10.1097/PAF.0b013e3182a186c8
23. Laeremans H, Hackeng TM, van Zandvoort MA, Thijssen VL, Janssen BJ, Ottenheijm HC, Smits JF, Blankensteijn JM (2011) Blocking of frizzled signaling with a homologous peptide fragment of wnt3a/wnt5a reduces infarct expansion and prevents the development of heart failure after myocardial infarction. Circulation: 124:1626–1635. doi:10.1161/CIRCULATIONAHA.110.976969
24. Laeremans H, Rensen SS, Ottenheijm HC, Smits JF, Blankensteijn WM (2010) Wnt/frizzled signalling modulates the migration and differentiation of immortalized cardiac fibroblasts. Cardiovasc Res 87:514–523. doi:10.1093/cvr/cvq067
25. Lewis CW, Owen CH, Zippirich DA, Sabiston DC Jr, Smith PK, Glower DD (1993) The effects of local ventricular pacing on recovery from regional myocardial ischemia. J Surg Res 54:360–367. doi:10.1016/j.sjre.1993.1058
26. Lindner D, Zietsch C, Tank J, Sossalla S, Fluschnik N, Hinrichs S, Maier L, Poller W, Blankenberg S, Schultheiss HP, Tschope C, Westermann D (2014) Cardiac fibroblasts support cardiac inflammation in heart failure. Basic Res Cardiol 109:428. doi:10.1007/s00395-014-0428-7
27. Oberhollenzer F, Eveson DJ, Walker DM, Yellon DM (1993) A single five minute period of rapid atrial pacing fails to limit infarct size in the in situ rabbit heart. Cardiovasc Res 27:597–601. doi:10.1093/cvr/27.4.597
28. Masci PG, Gananme J, Francone M, Desmet W, Lorenzoni V, Iacucci I, Barison A, Lombardi M, Agati L, Janssens I, Rademakers F, Dymarkowski S, Gheysens O, Van Cleemput J, Janssen BJ, Ottenheijm HC, Smits JF, Blankesteijn WM (2011) Wnt/frizzled signalling modulates the migration and differentiation of immortalized cardiac fibroblasts. Cardiovasc Res 97:343–347. doi:10.1161/CIRCULATIONAHA.110.936872
29. Mukherjee R, Rivers WT, Ruddy JM, Matthews RG, Koval CN, Pfylre RA, Chang EL, Patel RK, Kern CB, Stroud RE, Spinnale FG (2010) Long-term localized high-frequency electric stimulation within the myocardial infarct: effects on matrix metalloproteinases and regional remodeling. Circulation 122:20–32. doi:10.1161/CIRCULATIONAHA.110.936872
30. Ovize M, Kloner RA, Przyklenk K (1994) Stretch preconditions canine myocardium. Am J Physiol 266:H137–H146
31. Porter KE, Turner NA (2009) Cardiac fibroblasts: at the heart of myocardial remodeling. Pharmacol Ther 123:255–278. doi:10.1016/j.pharmthera.2009.05.002
32. Shah DJ, Kim HW, James O, Parker M, Wu E, Bonow RO, Judd RM, Kim RJ (2013) Prevalence of regional myocardial thinning and relationship with myocardial scarring in patients with coronary artery disease. JAMA 309:909–918. doi:10.1001/jama.2013.1381
33. Shuros AC, Salo RW, Florea VG, Pastore J, Kuskowski MA, Chandrashekhar Y, Anand IS (2007) Ventricular preexcitation modulates strain and attenuates cardiac remodeling in a swine model of myocardial infarction. Circulation 116:1162–1169. doi:10.1161/CIRCULATIONAHA.107.696294
34. Springeling T, Kirschaum SW, Rossi A, Baks T, Karamermer Y, Schulz C, Ouhlous M, Duncker DJ, Moelker A, Krestin GP, Serruys PW, de Feyter P, van Geuns RJ (2013) Late cardiac remodeling after primary percutaneous coronary intervention five-year cardiac magnetic resonance imaging follow-up. Circ J 77:81–88. doi:10.1253/circj.CJ-12-0043
35. Springeling T, Uittertijdik A, Rossi A, Gorse-Bakker C, Wielopolski PA, van der Giessen WJ, Krestin GP, de Feyter PJ, Duncker DJ, van Geuns RJ (2013) Evolution of reperfusion post-infarction ventricular remodeling: new MRI insights. Int J Cardiol 169:354–358. doi:10.1016/j.ijcard.2013.09.005
36. Stone GW, Chung ES, Stancak B, Svendsen JH, Fischer TM, Kueffer F, Ryan T, Bax J, Leon A, Investigators PRT (2016) Peri-infarct zone pacing to prevent adverse left ventricular remodelling in patients with large myocardial infarction. Eur Heart J 37:484–493. doi:10.1093/eurheartj/ehv436
37. Sun Y, Kiani MF, Postlethwaite AE, Weber KT (2002) Infarct scar as living tissue. Basic Res Cardiol 97:343–347. doi:10.1007/s00395-002-0365-8
38. Turner NA (2011) Therapeutic regulation of cardiac fibroblast function: targeting stress-activated protein kinase pathways. Future Cardiol 7:673–691. doi:10.2217/fca.11.41
39. Uittertijdik A, Herrmans KC, de Wijs-Meijler DP, Daskalopoulos EP, Reiss IK, Duncker DJ, Matthijs Blankensteijn W, Merkus D (2016) UM206, a selective Frizzled antagonist, attenuates adverse remodeling after myocardial infarction in swine. Lab Invest 96:168–176. doi:10.1038/labinvest.2015.139
40. van der Borne SW, van der Giessen WJ, Krestin GP, de Feyter PJ, Duncker DJ, van Geuns RJ (2013) Evolution of reperfusion post-infarction ventricular remodeling: new MRI insights. Int J Cardiol 169:354–358. doi:10.1016/j.ijcard.2013.09.005
41. van den Borne SW, van de Schans VA, Strzelecka AE, Vervoort-Peters HT, Lijnen PM, Cleutjens JP, Smits JF, Daemen MJ, Janssen BJ, Blankensteijn WM (2009) Mouse strain determines the outcome of wound healing after myocardial infarction. Cardiovasc Res 84:273–282. doi:10.1093/cvr/csp207
42. Vanagt WY, Cornelussen RN, Bayram T, De Vos S, Verheugt FW, van der Ploeg EP, Reiss IK, Duncker DJ, Matthijis Blankensteijn W, Merkus D (2016) UM206, a selective Frizzled antagonist, attenuates adverse remodeling after myocardial infarction in swine. Lab Invest 96:168–176. doi:10.1038/labinvest.2015.139
43. van den Borne SW, Diez J, Blankensteijn WM, Verjans J, Hofstra L, Narula J (2010) Myocardial remodeling after infarction: the role of myofibroblasts. Nat Rev Cardiol 7:30–37. doi:10.1038/nrcardio.2009.199
44. van den Borne SW, van de Schans VA, Strzelecka AE, Vervoort-Peters HT, Lijnen PM, Cleutjens JP, Smits JF, Daemen MJ, Janssen BJ, Blankensteijn WM (2009) Mouse strain determines the outcome of wound healing after myocardial infarction. Cardiovasc Res 84:273–282. doi:10.1093/cvr/csp207
45. Vanagat WY, Cornelussen RN, Bayram T, De Vos S, Verheugt FW, van der Ploeg EP, Reiss IK, Duncker DJ, Matthijis Blankensteijn W, Merkus D (2016) UM206, a selective Frizzled antagonist, attenuates adverse remodeling after myocardial infarction in swine. Lab Invest 96:168–176. doi:10.1038/labinvest.2015.139
47. Waltenberger J, Gelissen M, Bekkers SC, Vainer J, van Ommen V, Eerens F, Ruiters A, Houtuijsen A, Cuesta P, Strauven R, Mokelke E, Gorgels A, Prinzen FW (2014) Clinical pacing post-conditioning during revascularization after AMI. JACC Cardiovasc Imaging 7:620–626. doi: 10.1016/j.jcmg.2014.01.017

48. Weisman HF, Healy B (1987) Myocardial infarct expansion, infarct extension, and reinfarction: pathophysiologic concepts. Prog Cardiovasc Dis 30:73–110. doi:10.1016/0033-0620(87)90004-1

49. Weiss JL, Marino PN, Shapiro EP (1991) Myocardial infarct expansion: recognition, significance and pathology. Am J Cardiol 68:35D–40D. doi:10.1016/0002-9149(91)90259-N

50. Whyte JL, Smith AA, Helms JA (2012) Wnt signaling and injury repair. Cold Spring Harb Perspect Biol 4:a008078. doi:10.1101/cshperspect.a008078